secwatch.observer — SEC 8-K summary
======================================

Issuer:     Phio Pharmaceuticals Corp. (PHIO)
CIK:        0001533040
Form:       8-K
Filed at:   2025-12-23T23:59:59+00:00
Accession:  0001437749-25-038607
Event type: regulatory
Sentiment:  positive
Materiality: 0.65
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Phio Pharma gets FDA acceptance of PH-762 nonclinical study design; tox study Q1 2026
--------------------------------------------------------------------------------

- FDA accepted nonclinical protocol study design for PH-762; toxicology study to begin Q1 2026.
- Interim Phase 1b results: 6 complete responses among 16 evaluable cSCC patients; no dose-limiting toxicities.
- Company advancing cGMP drug product delivery in 2026, partially funded by recent financing.
- PH-762 well tolerated in all enrolled patients across five dose cohorts.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1533040/000143774925038607/0001437749-25-038607-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1533040/000143774925038607/phio20251222_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-25-038607

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer